Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644559 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
A Phase 2 study, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT07644559 is a Phase 2 study that is actively recruiting participants, run by Verastem. The registered enrollment target is 180 participants.
The verdict
NCT07644559, a Phase 2 study, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Interventions
- DRUG cetuximab
- DRUG VS-7375
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-06-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07644559
The ClinicalTrials.gov registry entry for NCT07644559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cetuximab is the first listed.
NCT07644559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07644559 about?
NCT07644559 is a clinical study titled "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer". This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
What is the current status of trial NCT07644559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-06-16. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07644559?
The interventions under investigation include: cetuximab (DRUG), VS-7375 (DRUG).
Who is sponsoring clinical trial NCT07644559?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.